Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6002 versus enfortumab vedotin in advanced urothelial carcinoma
NCT07374549Phase 2Not yet recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of CRB-701 in urothelial carcinoma (UC), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
CRB-701
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07374549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07374549.